U.S. markets closed
  • S&P Futures

    4,639.25
    +43.50 (+0.95%)
     
  • Dow Futures

    35,105.00
    +247.00 (+0.71%)
     
  • Nasdaq Futures

    16,239.50
    +188.50 (+1.17%)
     
  • Russell 2000 Futures

    2,267.50
    +24.20 (+1.08%)
     
  • Crude Oil

    71.74
    +3.59 (+5.27%)
     
  • Gold

    1,796.30
    +8.20 (+0.46%)
     
  • Silver

    23.43
    +0.30 (+1.28%)
     
  • EUR/USD

    1.1287
    -0.0033 (-0.29%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • Vix

    28.62
    +10.04 (+54.04%)
     
  • GBP/USD

    1.3336
    -0.0002 (-0.02%)
     
  • USD/JPY

    113.5370
    +0.2270 (+0.20%)
     
  • BTC-USD

    57,401.01
    +3,061.57 (+5.63%)
     
  • CMC Crypto 200

    1,431.32
    -24.09 (-1.66%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,746.49
    -5.13 (-0.02%)
     

Daniel Junius Is The Independent Director of GlycoMimetics, Inc. (NASDAQ:GLYC) And They Just Spent US$68k On Shares

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Even if it's not a huge purchase, we think it was good to see that Daniel Junius, the Independent Director of GlycoMimetics, Inc. (NASDAQ:GLYC) recently shelled out US$68k to buy stock, at US$3.40 per share. While that isn't the hugest buy, it actually boosted their shareholding by 111%, which is good to see.

View our latest analysis for GlycoMimetics

The Last 12 Months Of Insider Transactions At GlycoMimetics

Notably, that recent purchase by Daniel Junius is the biggest insider purchase of GlycoMimetics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of US$3.09. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Daniel Junius.

Daniel Junius bought 30.00k shares over the last 12 months at an average price of US$3.33. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqGM:GLYC Recent Insider Trading, March 11th 2020
NasdaqGM:GLYC Recent Insider Trading, March 11th 2020

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$3.0m worth of GlycoMimetics stock, about 2.2% of the company. I generally like to see higher levels of ownership.

What Might The Insider Transactions At GlycoMimetics Tell Us?

It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that GlycoMimetics insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing GlycoMimetics. You'd be interested to know, that we found 3 warning signs for GlycoMimetics and we suggest you have a look.

Of course GlycoMimetics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.